Issue 13

FIELD TRIP HEALTH HAS ANNOUNCED THE CLOSING OF ITS BOUGHT DEAL FINANCING

Field Trip Health, a leader in the development and delivery of psychedelic therapies, has announced that it has completed a financing deal which will allow the organisation to drive significant growth in 2021 and beyond.

“We are delighted to have the support of the investment community as we continue with our mission to increase access to psychedelic therapies both through the development of new drugs and products, and building the physical and digital infrastructure necessary to deliver these potentially life-transforming therapies.”

Joseph del Moral, Chief Executive Officer 

BUSINESS AND INVESTMENT


MindMed files its final prospectus in connection with its bought deal equity financing.


Awakn Life Sciences is set to open the UK’s first psychedelic clinic in January 2021.


VC fund committed to psychedelic-medicine development launches in the UK.


Beckley Psytech raises €15.5m to develop psychedelics for neurological disorders.


Better Life Pharma applies for patent protection of 2-Bromo-LSD formulation.


Psychedelic health company Novamind commences trading on the CSE.


Horizons to file prospectus to launch world’s first psychedelic stock index ETF.


Red Light Holland agrees to acquire psychedelic company Mera Life Sciences.


MagicMed establishes psilocybin- and DMT-derivatives patent portfolio.


Numinus completes first extraction of its psilocybe mushrooms.


Neonmind, a psychedelic-drug development company, starts trading on the CSE.


Big pharma set to take on prominent role in psychedelics sector.


Psyched Wellness commences pre-clinical trial of psychedelic Amanita Muscaria.


Mindset Pharma commences trading on the CSE and expands psychedelic portfolio.


Nova Mentis expands its drug portfolio with two additional psychedelic compounds.


PharmaTher signs LOI to sell psilocybin programme to Revive Therapeutics.


Pure Extracts commences study on psilocybin oral tablets, capsules and nasal gel.


Core One Labs acquires API-grade psilocybin producer Vocan Biotechnologies.

A German billionaire is aiming to improve access to psilocybin to help treat depression and anxiety.

The Psychedelics as Medicine Report: Second Edition

COULD PSYCHEDELIC MEDICINES OFFER HOPE AMIDST THE MENTAL HEALTH CRISIS CAUSED BY COVID-19?

Before the outbreak of the Coronavirus, the potential healthcare savings offered by psychedelic medicines in Europe was almost $100 billion. But now, after almost a year of a global health crisis, this figure could increase dramatically as mental health problems become more widespread and more serious as the pandemic continues.

Discover how psychedelic medicines could offer patients and health professionals hope in the fight against mental health issues in; The Psychedelics as Medicine Report: Second Edition.

REGULATION & LEGISLATION


New Hampshire court upholds religious freedom to use psilocybin mushrooms.


Health Canada approves first psilocybin treatment for terminally ill patient in Alberta.


Psychedelic-treatment advocates concerned over lack of information in Nova Scotia.


UK advocates campaign to use psychedelic mushrooms to treat patients with OCD.


Oregon’s 2021–23 budget includes funds to implement a psilocybin therapy programme.

RESEARCH AND SCIENCE


New study finds repeated ketamine infusions reduce severity of PTSD.


Scientists use AI to understand visual experiences induced by psychedelics.


Psychedelic therapies offer hope for treating severe mental anguish.


Canada commences trials of psilocybin psychotherapy for substance use disorders.


Study finds one psychedelic experience may lessen trauma of racial injustice.


Canada completes its first legal psychedelic-assisted therapy program.